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Human cytomegalovirus (HCMV) has been recently related with a lower susceptibility to
multiple sclerosis (MS). HCMV promotes an adaptive development of NK cells bearing the
CD94/NKG2C receptor with a characteristic phenotypic and functional profile. NK cells
are proposed to play an immunoregulatory role in MS, and expansion of the NKG2C(+)
subset was recently associated with reduced disability progression. To further explore
this issue, additional adaptive NK cell markers, i.e., downregulation of FcεRIγ chain
(FcRγ) and PLZF transcription factor, as well as antibody-dependent NK cell activation
were assessed in controls and MS patients considering HCMV serology and clinical
features. In line with previous reports, increased proportions of NKG2C(+), FcRγ(–), and
PLZF(–) CD56dim NK cells were found in HCMV(+) cases. However, PLZF(–) NK cells
were detected uncoupled from other adaptive markers within the CD56bright subset from
HCMV(+) cases and among CD56dim NK cells from HCMV(–) MS patients, suggesting
an additional effect of HCMV-independent factors in PLZF downregulation. Interferon-β
therapy was associated with lower proportions of FcRγ(–) CD56dim NK cells in HCMV(+)
and increased PLZF(–) CD56bright NK cells in HCMV(–) patients, pointing out to an
influence of the cytokine on the expression of adaptive NK cell-associated markers.
In addition, proportions of NKG2C(+) and FcRγ(–) NK cells differed in progressive MS
patients as compared to controls and other clinical forms. Remarkably, an adaptive NK
cell phenotype did not directly correlate with enhanced antibody-triggered degranulation
and TNFα production in MS in contrast to controls. Altogether, our results provide novel
insights into the putative influence of HCMV and adaptive NK cells in MS.
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INTRODUCTION
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system characterized
by a highly variable clinical course. Both genetic and environmental factors are involved in MS,
with an influence of herpesvirus infections supported by seroepidemiological studies. Whereas
Epstein–Barr virus (EBV) is consistently associated with MS and might play a pathogenic role
as an environmental trigger (1, 2), human cytomegalovirus (HCMV) was recently related to
lower MS susceptibility (3–6); however, the basis for these observations remains uncertain.
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HCMV establishes a lifelong latent infection whose prevalence
appears inversely related with socioeconomical development and,
in line with the “hygiene hypothesis,” the reported associations
with MS might be indirectly linked to the exposure to other
environmental factors. On the other hand, a putative influence
of HCMV in MS immunopathology is conceivable (7), as this
herpesvirus may exert a profound impact on the immune
system (8), and could potentially modulate the response to other
pathogens (i.e., heterologous immunity) (9, 10). Nevertheless,
whether HCMV may exert a beneficial or detrimental effect on
MS is currently uncertain (11).
T lymphocytes and natural killer (NK) cells play
complementary key roles in controlling HCMV, which,
reciprocally, has developed a variety of immune evasion
mechanisms (12). HCMV has been reported to induce a
persistent reconfiguration of NK cell compartment, both in
healthy individuals and under pathological conditions. The
magnitude of this effect is variable and hallmarked by the
differentiation and expansion of functionally mature NK
cells displaying high levels of the CD94/NKG2C activating
receptor encompassed by additional phenotypic and functional
changes (13–16). Human adaptive NKG2C(+) NK cells
are contained within the major circulating CD56dim subset,
which mediates cytotoxicity and cytokine production upon
interaction with target cells, either directly or through IgG
engagement of FcγRIIIA (CD16A). As compared to other
subsets, adaptive NKG2C(+) NK cells effectively mediate
antibody-dependent effector functions, particularly cytokine
production (17, 18). Additional associated-adaptive NK cell
markers include epigenetic silencing of the promyelocytic
leukemia zinc finger (PLZF) transcription factor, with unknown
functional implications in NK cells (17, 19–21), and loss of the
FcεRI gamma chain (FcRγ) adaptor coupled to CD16, whose
replacement by the ζ chainmay enhance antibody-dependent NK
cell activation (17, 19, 22, 23). Some adaptive NK cell-associated
features have also been detected in NKG2C(–) NK cell subsets,
suggesting that NK cell differentiation is independent of NKG2C
expression and may be induced by stimuli other than HCMV
(17, 18, 24). Moreover, adaptive NK cell differentiation may
not be a coordinated process, as supported by the delayed FcRγ
loss observed in adaptive NK cells following HCMV infection
in hematopoietic stem cell transplantation recipients (25). The
cellular and molecular mechanisms underlying the development
of adaptive NK cells and their implications in human health
remain partially defined.
NK cells have been previously studied in the context of
MS (26, 27), and changes associated with the response to
some immunomodulatory therapies have been reported (28,
29), proposing an immunoregulatory role played by the minor
circulating CD56bright NK cell subset (30). These cells display
a CD16(–) NKG2A(+) phenotype and have a limited cytotoxic
capacity but efficiently produce cytokines, constituting the
predominant subset in peripheral lymphoid tissues. However,
the role of NK cells in MS immunology is only partially
understood. Recently, we described an association of HCMV-
induced expansion of NKG2C(+) NK cells with a lower risk of
disability progression in MS, suggesting an influence of these
lymphocytes on the clinical course (31). In the present study,
we aimed to further explore whether HCMV and adaptive
NK cells play a protective role in MS. Adaptive NK cell
immunophenotype and antibody-triggered NK cell activation
against EBV-transformed B cell lines were evaluated in MS
patients considering their HCMV serostatus and clinical profile,
providing further insights into the involvement of NK cells in
this disease.
MATERIALS AND METHODS
Study Design and Population
A case–control study of MS patients was designed to analyze
adaptive NK cell markers and antibody-dependent NK cell
activation in accordance to HCMV serostatus and clinical
characteristics. MS patients diagnosed based on McDonald
criteria 2010 from Hospital del Mar, IMIM (Barcelona) and
Hospital Ramón y Cajal (Madrid) (REEM, Spanish Network
for MS research) were recruited from routine clinical visits.
In addition, a subgroup of MS patients was prospectively
evaluated after onset of interferon-beta (IFNβ) therapy to
assess the influence of this treatment on adaptive NK cells.
We excluded patients on disease-modifying therapies known
to deplete peripheral lymphocytes or alter their trafficking
(e.g., natalizumab, fingolimod, dimethyl fumarate), as well as
those undergoing corticosteroid treatment in the last 30 days,
pregnancy, or any severe concomitant disease. The following
demographic and clinical characteristics were evaluated in every
case: age, sex, disease duration, MS form (RRMS: relapsing–
remitting MS, SPMS: secondary progressive MS, PPMS: primary
progressive MS), disability scores (EDSS: Expanded Disability
Status Scale, MSSS: multiple sclerosis severity score) and
treatment. Healthy controls matched for age and sex were
recruited from the same geographical area.
The study was approved by the local Ethics Committee,
including participants after written informed consent. Blood
samples obtained from venous puncture were obtained
from controls and MS patients, performing standard
clinical diagnostics test to evaluate EBV-(LIASON R©) and
HCMV-specific circulating antibodies (Roche R©, Cobas602).
Analysis of NK Cell Immunophenotype
Peripheral blood mononuclear cells (PBMCs) from 47 healthy
controls and 151MS patients were isolated from blood samples
collected in EDTA tubes using Ficoll–Hypaque density gradient
centrifugation and cryopreserved in fetal calf serum with 10%
dimethyl sulfoxide until analysis. Sample staining for flow
cytometry analysis was performed using anti-NKG2A (clone
Z199) indirectly labeled with a secondary goat anti-mouse PE-
Cy7 (Biolegend) and the following fluorochrome-conjugated
antibodies: anti-CD3-PerCP (BD Pharmigen), anti-CD56-APC
(Biolegend), antiCD16-eFluor450 (eBioscience), and NKG2C-
PE (R&D Systems). For the analysis of FcRγ (MS, n = 139;
controls n = 47) and PLZF expression (MS, n = 86; controls
n = 26), cells were treated with a fixation/permeabilization kit
(BD Biosciences) followed by incubation with anti-FcRγ-FITC
(Millipore) and anti-PLZF-PE CF594 (BD Biosciences). Samples
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were acquired in LSRFortessa (BD Biosciences) and data were
analyzed using FlowJo software (Tree Star, Oregon, USA), using
the gating strategy shown in Figure 1.
Functional Assessment of
Antibody-Dependent NK Cell Activation
PBMCs from 42MS patients (22 RRMS, 8 SPMS and 12
PPMS) and 17 controls matched for HCMV serostatus were
incubated overnight at 37◦C with recombinant IL-2 (200
U/ml). The response of NK cells to the HLA class I-
defective 721.221 B-lymphoblastoid cell line with or without
rituximab (50 ng/ml) was assessed following a 4-h incubation
(E/T = 1/1). A complementary approach was performed using
EBV(+) AKBM cells as targets following induction of the
lytic cycle in the presence of EBV(+) or EBV(–) sera, as
previously described (32, 33). Surface expression of CD107 as a
marker of degranulation and intracellular TNFα production was
analyzed by flow cytometry as previously reported (34), using
the anti-CD107-APC (BD Pharmigen) monoclonal antibody
during incubation together with monensin (GolgiStop R©; BD)
and brefeldin (GolgiPlug R©; BD). Cultures were then stained
with anti-CD3-PerCP (BD Pharmigen), anti-CD56-APC-Cy7
(Biolegend), and anti-NKG2C-PE (R&D System), permeabilized,
fixed and stained intracellularly with anti-TNFα-CFBlue (labeled
by Immunostep), anti-FcRγ-FITC (Millipore), and anti-PLZF-PE
CF594 (BD Biosciences). Data acquisition was performed with an
LSRFortessa cytometer (BD Biosciences).
Multidimensional Flow Cytometry Analysis
Using Barnes-Hut t-SNE
A multidimensional flow cytometry analysis was performed as
previously described (35), compensating raw flow cytometry
data using FlowJo software (Tree Star, Oregon, USA) and
later imported into R using flowCore and openCyto packages.
Lymphocytes were gated on forward scatter and side scatter
characteristics and then on CD56dim NK cells. FITC channel
was normalized using flowStats R package in order to reduce
experimental variability on fluorescence intensity. Subsequently,
randomly selected data from 500 CD56dim NK cells per sample
was concatenated. The most positive and negative one per
mille values for each parameter were reduced to their less
extreme border. Next, Barnes-Hut t-SNE was conducted using
the Rtsne package. Graphics were produced using ggplot2 and
RcolorBrewer R packages.
Statistical Analysis
Normal distribution was assessed using Kolmogorov–Smirnov
test. Continuous variables were expressed as mean ± standard
deviation (SD) or median (first–third quartile) for parametric
and non-parametric variables, respectively. Relationship between
continuous and dichotomous variables was assessed by Student’s
t-test or Mann–Whitney U-test, respectively. Pearson or
Spearman correlation coefficients were calculated for pairwise
comparison of continuous variables. Wilcoxon test for paired
samples was used to compare matched prospectively followed-
up samples before and after IFNβ therapy. Three-dimensional
Venn analysis evaluated the co-expression of adaptive markers
in NK cells. Multivariate lineal regression analysis determined
predictors for adaptive NK cell markers adjusting the models
for HCMV serostatus, clinical variables, and IFNβ treatment.
Results were considered significant at the two-sided level of 0.05.
Analyses were performed using SPSS v.23 software.
RESULTS
HCMV-Related Expansion of Adaptive NK
Cells in MS Patients
We comparatively studied in controls and MS patients the
influence of HCMV on the expression of adaptive NK cell
differentiation markers (NKG2C, FcRγ, and PLZF) based on
the gating strategy for flow cytometry analysis illustrated in
Figure 1. Demographic and clinical characteristics ofMS patients
and controls are shown in Table 1. In our study, HCMV
seroprevalence was comparable in both groups (Table 1), and no
clinical differences were observed in MS patients associated with
HCMV serostatus (data not shown).
HCMV seropositivity was associated with greater proportions
of NKG2C(+) NK cells, with no significant differences between
MS patients and controls (Figure 2A). The expansion of
NKG2C(+) cells was confined to the CD56dim NK cell
subset, whereas detection of CD56bright NKG2C(+) NK cells
appeared unrelated to HCMV serology (Figure 2A). Similarly,
the frequency of CD56dim FcRγ(–) NK cells was also increased
in HCMV(+) patients and controls as compared to HCMV(–)
individuals (Figure 2B). By contrast, HCMV(+) controls andMS
patients showed increased proportions of PLZF(–) cells not only
in CD56dim NK cells but, remarkably, also among the CD56bright
subset (Figure 2C); these PLZF(–) NK cells were confirmed
to display the characteristic CD56bright NKG2A(+) CD16(–)
phenotype (Supplementary Figure 1). Of note, an increased
frequency of PLZF(–) cells was also detected among CD56dim NK
cells from HCMV(–) MS patients as compared to seronegative
controls (Figure 2C). Overall, these results support previous
studies describing the HCMV-related expansion of adaptive NK
cells displaying the NKG2C(+), FcRγ(–), and PLZF(–) markers
in CD56dim NK cells; however, a lack of PLZF expression
associated to HCMV seropositivity was also perceived in the
CD56bright NK cell subset, in both controls and MS patients, in
addition to an influence of HCMV-independent factors in PLZF
downregulation in CD56dim NK cells found in MS cases.
Relationship Between Adaptive NK Cell
Markers in MS Patients and Controls
We next evaluated the relation of adaptive NK cell markers
in CD56dim NK cells from controls and MS patients.
Three-dimensional Venn diagrams illustrated that NK cells
co-expressing adaptive NK cell markers were increased in
HCMV(+) compared to HCMV(–) MS patients (Figures 3A,B).
The presence in MS patients of increased proportions of PLZF(–)
CD56dim NK cells without other adaptive markers was also
confirmed (Figure 3A).
t-SNE multidimensional analysis of adaptive markers in
CD56dim NK cells (Figure 3C) revealed an HCMV-related
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FIGURE 1 | Gating strategy for adaptive NK cells. Lymphocytes were identified based on their forward scatter (FCS) and side scatter (SSC) characteristics, defining
NK cells as CD3(–) CD56(+) lymphocytes. Representative examples were selected based on the expression of adaptive NK cell markers, showing a case with a low
expression of the three adaptive markers (MS.01), a case with low NKG2C(+), FcRγ(–), and PLZF(–) expression in CD56dim NK cells but with a higher proportions of
PLZF(–) CD56bright NK cells (HC.01), and a case with higher proportions of NKG2C(+), FcRγ(–), and PLZF(–) CD56dim NK cells.
expression of NKG2C, more pronounced in controls than in MS
patients. By contrast, NKG2C(–) FcRγ(–) PLZF(–) NK cells were
more evident in MS patients than in controls, with a less marked
relation to HCMV serology (Figure 3C). These results further
point out an uncoupled expression of adaptive markers in NK
cells from MS patients as compared to controls, suggesting the
influence of factors other than HCMV.
Influence of IFNβ Therapy on Adaptive NK
Cells in RRMS
We next evaluated the impact of IFNβ therapy on adaptive
NK cell markers in RRMS (mean time of treatment, 7.0 ±
4.2 years). As previously reported (36), IFNβ-treated patients
displayed increased proportions of CD56bright NK cells as
compared to untreated cases (14.8% ± 11.6 vs. 8.3% ±
7.1, p < 0.05), which appeared unrelated to any of the
adaptive markers analyzed (data not shown). IFNβ therapy
did not alter the effect of HCMV on the proportions of
NKG2C(+) CD56dim NK cells (Figure 4A). However, lower
proportions of FcRγ(–) CD56dim NK cells were found in
IFNβ-treated patients as compared to untreated cases (9.6%
± 8.2 vs. 19.3% ± 19.7, p < 0.05), a finding only perceived
in CD56dim NK cells from HCMV(+) but not in HCMV(–)
MS cases, who displayed low proportions of FcRγ(–) NK
cells independently of treatment (Figure 4B). Interestingly,
PLZF(–) CD56bright NK cells tended to increase in IFNβ-
treated HCMV(–) patients (Figure 4C), vanishing the differences
related to HCMV serostatus noticed in both CD56dim and
CD56bright NK cell subsets (Figure 2C). These results suggest
that HCMV-driven adaptive NK cell development in RRMS
might be modulated by IFNβ therapy. However, the above-
mentioned IFNβ-related modifications in adaptive markers were
not perceived in a subgroup of MS patients prospectively
followed after 1 year of treatment (Supplementary Figure 2),
indicating that the cytokine does not directly modify the adaptive
NK cell immunophenotype.
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TABLE 1 | Demographic and clinical characteristics of MS patients and controls.
Controls MS patients P-value* RRMS SPMS PPMS P-value#
n = 47 n = 151 n = 88 n = 44 n = 19
Age (years) 46.6 ± 13.3 50.1 ± 11.4 0.08 45.6 ± 10.0 55.0 ± 8.8 59.4 ± 13.0 <0.001
HCMV seroprevalence, n (%) 37 (78.7) 103 (68.7) 0.126 59 (67.8) 33 (75) 11 (57.9) 0.217
EBV seroprevalence, n (%) 40 (87) 147 (98.7) <0.01 86 (98.9) 43 (97.7) 18 (100) 0.152
Sex (female), n (%) 30 (63.8) 101 (66.9) 0.413 59 (67.0) 28 (63.6) 14 (73.7) 0.861
MS duration (years) – 15.1 ± 10.0 11.6 ± 9.1 21.5 ± 8.7 16.2 ± 9.8 <0.001
DMT, n (%) – 50 (33.1) 42 (47.7) 7 (15.9) 1 (5.3) <0.001
DMT-naive, n (%) – 47 (34.1) 22 (28.9) 9 (20.9) 16 (84.2) <0.001
EDSS – 3.5 (2.0–6.0) 2.0 (1.0–3.0) 6.5 (5.5–7.5) 6.0 (4.5–7.0) <0.001
MSSS – 4.23 ± 2.92 2.60 ± 2.20 6.58 ± 2.25 6.56 ± 1.91 <0.001
2y-RR – 0.19 ± 0.41 0.34 ± 0.52 0.01 ± 0.08 0.0 ± 0.0 <0.001
ARR – 0.37 ± 0.41 0.42 ± 0.42 0.52 ± 0.39 0.01 ± 0.02 <0.001
Values are expressed as mean ± SD or median (1st−3rd quartile). HCMV, human cytomegalovirus; EBV, Epstein–Barr virus; DMT, disease-modifying therapy (interferon-beta, n = 45;
glatiramer acetate, n = 5), EDSS, Expanded Disability Status Scale; MSSS, multiple sclerosis severity score; 2y-RR, relapsing rate in the previous 2 years; ARR, annualized relapsing
rate; RRMS, relapsing–remitting MS; SPMS, secondary progressive MS; PPMS, primary progressive MS. *P-values comparing controls and MS patients using t test or Mann–Whitney
U-test. #P-values comparing RRMS, SPMS, and PPMS patients using one-way ANOVA.
FIGURE 2 | Expression of adaptive markers in NK cells from controls and MS patients according to HCMV serostatus. (A) Proportions of NKG2C(+), (B) FcRγ(–), and
(C) PLZF(–) in CD56dim and CD56bright NK cells from healthy controls (HC) and MS patients according to HCMV serostatus. Higher proportions of NKG2C(+), FcRγ(–),
and PLZF(–) in CD56dim NK cells were found in HCMV(+) as compared to HCMV(–) cases (A–C), in addition to higher proportion of PLZF(–) NK cells perceived in the
CD56bright subset (C). Increased proportions of PLZF(–) CD56dim NK cells were also found in HCMV(–) MS patients as compared to HCMV(–) controls (C). NKG2C,
MS = 151, HC 139; FcRγ, MS = 139, HC = 47; PLZF, MS = 86, PLZF = 26. Individuals with an NKG2C del/del genotype (HC, n = 1; MS, n = 6) were excluded from
the analysis of NKG2C expression. P values (Mann–Whitney U test): * <0.05, ** <0.01, *** <0.001, **** <0.0001.
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FIGURE 3 | Interrelationship of adaptive NK cell markers in MS. Venn diagrams depicting the proportions of NKG2C(+), FcRγ(–), and PLZF(–) CD56dim NK cells in
healthy controls (HC) (n = 26) and MS patients (n = 86) (A), and stratifying results according to HCMV serostatus (B). Values expressed the mean proportion for each
group. P-values (Mann–Whitney U-test): ** <0.01, comparing controls vs. MS patients; ##<0.01, comparing HCMV(–) vs. HCMV(+). (C) t-SNE plots of NKG2C,
NKG2A, FcRγ, and PLZF expression in CD56dim NK cells evaluated in HC and MS patients according to HCMV serostatus.
Distribution of Adaptive NK Cells in MS
Patients According to Clinical Forms
ConsideringMS form, NKG2C(+) CD56dim NK cell proportions
were lower in PPMS patients as compared to SPMS patients
(Supplementary Figure 3A). By contrast, proportions of
FcRγ(–) NK cells appeared greater in SPMS patients as
compared to RRMS, in both CD56dim and CD56bright
NK cells (Supplementary Figure 3B). No differences were
observed for PLZF expression according to MS form
(Supplementary Figure 3C). After multivariate regression
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FIGURE 4 | Influence of IFNβ therapy in the expression of adaptive markers in NK cells from RRMS patients. Proportions of NKG2C(+) (A), FcRγ(–) (B), and PLZF(–)
(C) in CD56dim and CD56bright NK cells according to the presence of IFNβ therapy and HCMV serostatus. The influence of IFNβ was mainly perceived in the
expression of FcRγ in CD56dim NK cells in HCMV(+) cases, and in PLZF expression, which vanished differences related to HCMV serostatus in both PLZF(–) CD56dim
and CD56bright NK cells. NKG2C(+): IFNβ-treated, n = 33, and untreated patients, n = 44; FcRγ: IFNβ-treated patients, n = 37, untreated patients, n = 33; PLZF,
IFNβ-treated patients, n = 20, untreated patients, n = 24. Individuals with an NKG2C del/del genotype (RRMS, n = 5) were excluded from the analysis of NKG2C
expression. P values (Mann–Whitney U-test): * <0.05, ** <0.01.
analysis, the association of MS form with adaptive markers
appeared independent of HCMV and IFNβ-therapy only for the
proportions of NKG2C(+) CD56dim and FcRγ(–) CD56bright NK
cells (Supplementary Table 1). No additional correlations were
observed between adaptive NK cell markers and age, disease
duration, disability scores, or disease activity (data not shown).
These results suggest that the expression of some adaptive NK
cell markers may vary in progressive MS forms independently of
the influence of HCMV and IFNβ therapy.
Adaptive NK Cell Markers and
Antibody-Dependent Activation in MS
In order to evaluate antibody-dependent NK cell functions,
degranulation and TNFα production were measured in
NK cells from 42MS patients and 17 controls following
stimulation with the 721.221 cell line in the absence or
presence of rituximab (Figure 5A). As expected, CD56dim
NK cells in controls and MS patients showed a greater
degranulation and TNFα production in the presence of
rituximab (Figure 5B). In addition, an increased degranulation
of CD56bright NK cells in the direct response to the
721.221 cell line without rituximab was perceived in MS
patients (Figure 5B). Comparable results were observed in
experiments using the EBV-infected AKBM cell line as target
(Supplementary Figure 4A).
We subsequently evaluated antibody-dependent NK cell
functions according to MS form (Figure 5C). RRMS patients
displayed increased proportions of degranulating CD56dim NK
cells as compared with controls and PPMS; moreover, the
proportions of TNFα-secreting cells were lower in PPMS as
compared to controls and other MS forms (Figure 5C). Similar
results for TNFα production were obtained using the AKBM cell
line (Supplementary Figure 4B). IFNβ therapy in MS patients
did not influence the results obtained in these experiments (data
not shown).
Next, we evaluated the relationship of adaptive markers in
CD56dim NK cells and antibody-triggered responses. In controls,
the proportions of NKG2C(+), FcRγ(–), and PLZF(–) CD56dim
NK cells appeared unrelated to degranulation, whereas a direct
correlation with TNFα production was observed (Figure 6). By
contrast, the proportions of adaptive NK cells in MS patients
did not correlate with TNFα secretion and, moreover, an inverse
relation between degranulation and the proportions of FcRγ(–)
and PLZF(–) CD56dim NK cells was detected (Figure 6); similar
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FIGURE 5 | Antibody-dependent NK cell activation in MS patients and controls. (A) Experimental design evaluating NK cell degranulation (CD107) and intracellular
TNFα production in functional experiments using 721.221 lymphoblastoid cell lines as NK cell targets. (B) CD107 expression and TNFα production by CD56dim and
CD56bright NK cells in controls and MS patients. (C) CD107 expression and TNFα production by CD56dim NK cells in controls and MS patients according to clinical
form. PBMC: peripheral blood mononuclear cells. Controls, n = 17; MS patients, n = 42 (RRMS, 22; SPMS, 8, PPMS 12). P-values (Mann–Whitney U-test for CD107
and Student’s t-test for TNFα expression): * <0.05, ** <0.01, *** <0.001, **** <0.0001.
observations were found in CD56bright NK cells fromMS patients
(data not shown). An analysis considering the co-expression
of adaptive markers in controls and MS patients showed
that antibody-triggered responses were greater in NKG2C(+)
CD56dim NK cells independently of FcRγ or PLZF expression
(Supplementary Figure 5).
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FIGURE 6 | Correlations between adaptive NK markers and antibody-dependent CD56dim NK cell activation. Spearman rank correlations (R) between proportions of
NKG2C(+), FcRγ(–), and PLZF(–) CD56dim NK cells and intracellular TNFα production (A), and CD107 expression (B) in functional experiments using rituximab and
721.221 lymphoblastoid cell lines as NK cell targets. HC, healthy controls; MS, multiple sclerosis. Controls, n = 17; MS patients, n = 42 (RRMS, 22; SPMS, 8,
PPMS 12).
Overall, these results suggest that adaptive NK cell function
may differ in MS according to clinical form, being greater
in RRMS as compared to progressive MS forms; however, in
contrast to healthy individuals, an adaptive NK cell profile in
MS patients did not correlate with proficient antibody-triggered
effector functions.
DISCUSSION
Considering the high prevalence of lifelong HCMV infection
and its broad impact on the immune system (8), the possibility
that this herpesvirus might somehow impact the development
of autoimmune disorders is plausible (37). A lower HCMV
seroprevalence has been reported in studies of pediatric and
adult MS populations (3–7, 11), suggesting that this infection
might have a protective effect. Among different hypotheses to
explain how HCMV might influence MS, we considered the
involvement of NK cells, which have been previously related
with the disease (26–30). The virus promotes to a variable
extent an adaptive differentiation of NK cells (13–15, 17,
19), which effectively mediate antibody-triggered cytotoxicity
and cytokine production, thus potentially contributing to the
immune response against HCMV and other microbial pathogens
(10, 38–40). In line with reports relating HCMV with a reduced
MS susceptibility (3–5), an association of HCMV-driven adaptive
NKG2C(+) NK cell expansion with a lower risk of clinical
progression was previously described (31). Yet, it remains
uncertain whether and how adaptive NK cells might influence the
development and clinical course of MS.
In agreement with extensive observations in healthy blood
donors and different clinical settings, our results pointed out
that HCMV infection is the leading factor that promotes the
development of conventional adaptive NKG2C(+), FcRγ(–),
and PLZF(–) CD56dim NK cells in MS patients (17–19, 22,
23). In previous reports, an uncoupled distribution of the
expression of some adaptive NK cell-associated markers, with
potential functional implications, was noticed (17, 18, 25). In
this regard, we observed increased proportions of PLZF(–) NK
cells, but not of NKG2C(+) or FcRγ(–) NK cells, among the
CD56bright NK cell subset from HCMV(+) individuals. Such
phenotype may result from an influence of HCMV at early
stages of adaptive NK cell development, according to the linear
model of differentiation from CD56bright NK cells (41), but
also of HCMV-unrelated factors (20, 42), as suggested by the
detection of increased PLZF(–) CD56dim NK cells in HCMV(–)
MS patients.
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No significant differences in NKG2C expression were
perceived between controls and progressive forms; yet,
lower proportions of NKG2C(+) NK cells in PPMS as
compared to SPMS were detected, in line with the lower
NKG2C pattern of expression in MS patients observed in
the multidimensional analysis as well as in previous studies
with a larger number of cases (31). An additional factor
related with changes in the expression of adaptive NK cell
markers in MS was IFNβ therapy, which was associated
with reduced proportions of CD56dim FcRγ(–) NK cells
in HCMV(+) RRMS patients. Moreover, HCMV-related
differences in the proportions of PLZF(–) CD56dim and
CD56bright NK cell subsets vanished in IFNβ-treated cases, an
effect related with an increase of PLZF(–) cells in HCMV(–)
patients. However, no phenotypic changes in adaptive NK
cells were perceived in a subset of RRMS cases prospectively
followed up for 1 year after initiating IFNβ therapy, pointing
out that this effect likely results from complex mechanisms
eventually requiring a longer exposure to be perceived.
Further studies would be required to assess whether PLZF
downregulation might be related to clinical response to
IFNβ therapy.
Adaptive NK cells have been reported to effectively mediate
antibody-triggered effector functions, particularly cytokine
production (22, 23, 34). NK cell activation upon incubation
with rituximab-coated 721.221 cells was mainly exerted by
CD56dim NK cells, without significant differences between
controls and MS patients, as previously reported (43). Other
clinical variables (i.e., age and IFNβ-therapy) appeared as
well unrelated with antibody-triggered responses mediated by
CD56dim NK cells (data not shown). Notwithstanding, NK
cell activation differed in MS according to the clinical form,
being lower in PPMS as compared to RRMS patients. Similar
results were obtained using as a target the AKBM cell line,
suggesting a comparable pattern of NK cell response against EBV-
infected targets. In accordance to previous studies addressing
the relation of adaptive markers with NK cell antibody-
triggered function (18, 25, 44), a proficient antibody-dependent
activity was related to NKG2C expression in CD56dim NK
cells rather than to other adaptive-associated markers. This
finding, in conjunction with the low NKG2C expression found
in progressive MS (31), deserves attention, suggesting that an
adaptive NK cell dysfunction may be associated with a risk of
disability progression.
Based on our observations, some considerations need to be
made regarding the putative connection of HCMV infection and
adaptive NK cells with MS immunopathology. First, the ability
of NK cells to eliminate activated T lymphocytes suggested that
they may play a relevant immunoregulatory role in the context
of MS (27, 28, 30). Yet, adaptive NK cells do not effectively
exert this function (17), possibly reflecting their expression
of KIRs and ILT2 HLA class I-specific inhibitory receptors.
Second, given their CD16-triggered antibody-dependent effector
functions and proliferation, adaptive NK cells likely participate
in the immune response to different microbial pathogens (17,
19, 22, 40). Thus, HCMV-induced adaptive NK cells might
contribute to the control of other herpesviruses proposed to
be involved in MS, as supported by their participation in
the marked antibody-dependent response against EBV-infected
cells (33). In this regard, the adaptive NK cell phenotype
in MS patients was not associated with proficient antibody-
dependent effector functions, in contrast to the pattern of
response observed in healthy donors. Third, PLZF(–) CD56bright
NK cells were detected in HCMV(+) controls and MS patients
and, moreover, IFNβ therapy was associated with increased
PLZF(–) CD56bright NK cells in HCMV(–) RRMS. This finding
deserves further attention in the context of the regulatory role
of CD56bright NK cells and their contribution to control EBV
infection (45, 46).
In conclusion, our results provide novel insights into
the putative influence of HCMV in MS involving the NK
cell compartment. The study shows that the distribution
of adaptive NK cell markers in MS may vary not only
depending on HCMV seropositivity but also on IFNβ therapy
and disease form, revealing differences in their antibody-
dependent activation as compared to healthy individuals.
Further studies are required to explore the involvement of
HCMV in the immune response to EBV in MS patients,
and the putative influence of HCMV-unrelated factors in
PLZF downregulation.
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